Search
for
Sort by
Research 841–870 of 880
- Hypertrichosis, trichomegaly, and androgenic alopecia related to cetuximab treatment
- Efficacy and safety of deuruxolitinib, an oral selective Janus kinase 1/2 inhibitor, in adults with alopecia areata: Results from the THRIVE-AA2 Phase 3, randomized, double-blind, controlled trial
- SALT score distribution with ritlecitinib treatment up to 24 months in alopecia areata
- 51840 Efficacy of the Oral JAK1/JAK2 Inhibitor Deuruxolitinib in Adult Patients with Moderate to Severe Alopecia Areata: Pooled Results from the Multinational Double-Blind, Placebo-Controlled THRIVE-AA1 and THRIVE-AA2 Phase 3 Trials
- Clinical aspect, pathogenesis and therapy options of alopecia induced by hormonal therapy for breast cancer
- Association of resilience and perceived stress in patients with alopecia areata: A cross-sectional study
- Transdermal delivery of a new hair growth promoting solution in patients with hair loss
- Hirsutism following the use of bimatoprost eyedrops for glaucoma
- Patient preferences in the treatment of alopecia areata: A review of the literature
- A new era for alopecia areata: New treatments and improved knowledge of the condition
- Type 2 Diabetes Mellitus and Demodex folliculorum Infestation: A Cross-Sectional Study in Peruvian Patients
- Content validity of five single‐item instruments in adolescents with alopecia areata
- Management of Alopecia Due to Cancer Therapies
- Redefining hair restoration with instant results – Is bio-enhanced simultaneous transplant long hair FUE the future?
- Use of oral Janus kinase inhibitors for the treatment of severe alopecia areata: narrative review and real-world experience
- A systematic review and meta‐synthesis of qualitative studies of alopecia: Managing identity and appearance changes
- Pathophysiology of Androgenetic Alopecia and Implications for Treatment: An Overview of Current Literature
- Clinical Trial Eligibility in Real‐World Alopecia Areata Patients Treated With Baricitinib
- Real-World Effectiveness of JAK Inhibitors for Alopecia Totalis and Alopecia Universalis: A Single-Center Experience
- A Patient Preference-Weighted Quantitative Benefit-Risk Analysis of Ritlecitinib for Alopecia Areata to Inform Medical Decision Making
- Frontal Fibrosing Alopecia and the Role of Cosmeceuticals in Its Pathogenesis
- Chitosan Nanoparticles for Topical Drug Delivery in Chemotherapy-Induced Alopecia: A Comparative Study of Five Repurposed Pharmacological Agents
- Efficacy and safety of tofacitinib in patients with total and universal alopecia- A retrospective evaluation of 69 patients
- Using patient preference to inform ritlecitinib dose selection for alopecia areata treatment
- Baricitinib Effectiveness in JAKi‐Naïve and Tofacitinib‐Exposed Patients: A Prospective Study in Alopecia Areata
- Latanoprost
- Tissue expansion and follicular unit extraction hair restoration in rehabilitation of a severe postburn deformity of neck and beard region
- Diffuse Lichen Planopilaris Masquerading as Diffuse Alopecia Areata
- Multi-omics analysis of functional substances and expression verification in cashmere fineness
- Establishing the financial burden of alopecia areata and its predictors